Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 4 of 16
Genetic Testing for All Breast Cancer Patients (GET FACTS)
NCT04245176
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
NCT03835819
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
NCT03974217
A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer
NCT03970083
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
NCT03912064
GENetic Education Risk Assessment and TEsting Study
NCT03762590
'ADVANCE' (A Pilot Trial)
NCT03858322
Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
NCT03749421
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT03789110
Elevate! : An Elderly Breast Cancer Cohort Study
NCT03818087
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
NCT03740334
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
NCT03716180
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
NCT03668340
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758
Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT03641755
Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue
NCT03657628
Niraparib in Patients With Pancreatic Cancer
NCT03601923
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
NCT03587740
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
NCT03580928
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
NCT03534323
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
NCT03483012
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
NCT03422003
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
NCT03341936
Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases
NCT03391362
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03392246
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
NCT03414684
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT02876302
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
NCT03333616
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
NCT03070236
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
NCT03141671
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT03236428
Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer
NCT03277469
Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03147287
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
NCT03152318
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
NCT03085719
Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
NCT03122717
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
NCT03075072
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
NCT03054896
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03020030
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
NCT03060720
A Study of Abemaciclib in Recurrent Glioblastoma
NCT02981940
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
NCT02880319
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
NCT02912572
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
NCT02873962
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
NCT02919683
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
NCT02852655
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
NCT02670525
Implementation of a System-level Tobacco Treatment Intervention
NCT02816697
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
NCT02764541
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
NCT02787369
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.